Merck

September 26, 2017September 26, 2017

Keytruda Approved in Canada for Treatment of Metastatic NSCLC

News

Merck’s Keytruda (pembrolizumab) is now available as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) in Canada. Adults whose tumors express high PD-L1, along with a ... Read more

July 5, 2016July 5, 2016

Lung Cancer Therapy Keytruda, Already OK’d for Different Cancers, Recommended for Approval in EU

Lung Cancer, News

Merck recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of the drug Keytruda (pembrolizumab), to be used ... Read more

October 29, 2015October 29, 2015

Merck’s NSCLC Drug Keytruda Outperforms Established Chemotherapy Drug

Lung Cancer, News

Merck recently announced topline data from the KEYNOTE-010 clinical trial assessing pembrolizumab as a treatment for patients with advanced non-small-cell lung cancer (NSCLC), determining that the study met its initial endpoint. Pembrolizumab (formerly MK-3475 and lambrolizumab, ... Read more

October 5, 2015October 5, 2015

Merck’s Keytruda Receives FDA Approval for Treatment of Advanced Non-small Cell Lung Cancer

Lung Cancer, News

The US FDA recently granted accelerated approval to Merck’s Keytruda (pembrolizumab) as a treatment for advanced (metastatic) non-small cell lung cancer (NSCLC) in patients with disease progression after other therapies have already ... Read more

June 4, 2015June 4, 2015

FDA Accepts Supplemental Biologics License Application For KEYTRUDA

Lung Cancer, News

Merck recently announced that the U.S. Food and Drug Administration (FDA) has agreed to review a supplemental Biologics License Application (sBLA) for the company’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), with the ... Read more

February 18, 2015February 18, 2015

Ongoing Clinical Trial Studying the Efficacy of Pembrolizumab in Non-Small Cell Lung Cancer

Lung Cancer

A Phase II clinical trial supervised by Joshua Bauml of Penn’s Abramson Cancer Center will assess whether Pembrolizumab, a drug already in use for melanoma treatment, can improve survival in ... Read more